Document is current

Article History

Received: 11 October 2022

Accepted: 7 February 2023

First Online: 21 February 2023

Declarations

:

: Not applicable.

: Not applicable.

: JdC received advisory fees from Merck Sharp & Dohme, Hoffmann-La Roche, Bristol-Myers Squibb, AstraZeneca, Pfizer, PharmaMar, Boehringer Ingelheim, Takeda, and Tesaro outside the submitted work. AI received advisory fees from Hoffmann-La Roche, Pfizer, BMS, Sanofi, Amgen, and AstraZeneca outside the submitted work. RC-B received advisory fees from Boehringer-Ingelheim, Janssen, Merck Sharp & Dohme, Hoffmann-La Roche, Amgen Inc, GlaxoSmithKline, Novartis, and Pfizer outside the submitted work. VE-V received advisory fees from Astellas, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Merck Sharp & Dohme, Novartis, and Pfizer outside the submitted work. AM-M received advisory fees from Bristol-Myers Squibb, Hoffmann-La Roche, Merck Sharp & Dohme, Pfizer, Boehringer Ingelheim, Merck Sharp & Dohme, and AstraZeneca outside the submitted work. IS received advisory fees from Hoffmann-La Roche outside the submitted work. AM reports a relationship with University Hospital MutuaTerrassa that includes consulting or advisory. EF has no conflict of interest outside the submitted work. DC is employee of Hygeia Consulting which received funding from Roche to conduct the analysis. NA is employee of Roche.